RxDoctor Payments Data

Joshua Goldman, DO

Internal Medicine · Pittsburgh, PANPI 1831165877

Payments from drug & device makers

$16,410in general payments, 2019–2025

Across 975 payments — averaging $16.83 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$3K
  • Pfizer$2K
  • AbbVie$2K
  • GSK$2K
  • Lilly USA, LLC$1K
  • Abbott$871
  • plus $7K from 39 others

What the payments were for

  • Food & beverage$16,398100%
  • Education$120%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$16,410 in reported general payments places this provider in the 95th percentile of 5,705 internal medicine providers in Pennsylvania.

See all internal medicine providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$103,574
Medicare patients
241
Services billed
2,635

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban321$228,500
MounjaroTirzepatide89$124,351
OzempicSemaglutide65$79,404
Trelegy ElliptaFluticasone/Umeclidin/Vilanter70$53,762
JardianceEmpagliflozin56$48,293
XareltoRivaroxaban41$37,047
CreonLipase/Protease/Amylase21$31,672
TrulicityDulaglutide25$29,585
EntrestoSacubitril/Valsartan31$27,845
Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog29$26,333
Breo ElliptaFluticasone/Vilanterol17$10,580
Atorvastatin Calcium867$8,979
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr16$8,250
Humalog Kwikpen U-100Insulin Lispro26$8,068
Toujeo SolostarInsulin Glargine,hum.Rec.Anlog14$7,929

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis, Abrysvo$1,649$234,767341 claims
Lilly USA, LLCMounjaro, Trulicity$1,064$153,936114 claims
Novo NordiskOzempic$2,585$79,40465 claims
GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta$1,522$72,591103 claims
Boehringer IngelheimJardiance$347$48,29356 claims
Johnson & JohnsonXarelto$431$37,04741 claims
AbbVieCreon$1,553$31,67221 claims
NovartisEntresto$283$27,84531 claims
MerckVerquvo$352$4,36013 claims
Almatica Pharma LLCSertraline Hcl$44$2,123143 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 5,705 internal medicine providers in Pennsylvania.

Other internal medicine in Pittsburgh

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →